All news

Moderna rises about 5% premarket as Bancel credits new products and geographic spread

CNBC via 10bmnews · · AI-summarised by FinFlash

Moderna shares rose about 5% in premarket trading after third-quarter results beat estimates. Chief executive Stephane Bancel said new products and geographic diversification drove the strong quarter, with the next-generation Covid vaccine showing a full-year impact and the stand-alone flu shot getting a limited launch in 2026. The stock is up more than 700% this year, largely on its Merck cancer vaccine partnership.

So What?

The rise is modest next to the size of the beat, for a stock already up more than 700% this year. Follow-through depends on guidance detail on the morning call.

Read original source

MRNA company analysis

Understand the context

Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.